Dr Jo Ann Nicholas, EDD | |
87 Cherry Ln, Airmont, NY 10952-4301 | |
(845) 357-6225 | |
Not Available |
Full Name | Dr Jo Ann Nicholas |
---|---|
Gender | Female |
Speciality | Audiologist |
Location | 87 Cherry Ln, Airmont, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164869145 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | 000535-1 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Jo Ann Nicholas, EDD 525 W 120th St, New York, NY 10027-6605 Ph: (212) 678-3408 | Dr Jo Ann Nicholas, EDD 87 Cherry Ln, Airmont, NY 10952-4301 Ph: (845) 357-6225 |
News Archive
Smith & Nephew's Endoscopy Division today announced the launch of the DYONICS™ RF System, which incorporates a compact generator with a family of probes for aggressively removing defects and smoothing soft tissue during arthroscopic surgery.
At a recent hearing of the House Subcommittee on Africa and Global Health, "[i]nternational health organisations working to help check the spread of AIDS in Africa said meagre increases in funds from the U.S. government this year would be a step backwards. Some experts also emphasised that prevention must get appropriate attention in any fight against the disease," Inter Press Service reports.
With a $450,000 grant from the National Institutes of Health, researchers at Worcester Polytechnic Institute will analyze how mechanical forces and cellular growth factors affect the growth and development of human heart valves to advance the long-term goal of using tissue engineering to develop replacement valves that are more natural and longer-lasting than current replacement valves.
On the heels of its successful 2009 campaign, CUTCO Cutlery Corp. has announced it will recommit to the American Heart Association's Go Red For Women® movement for another year.
Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.
› Verified 6 days ago